BIBLIOGRAFÍA.
1. Schrump DS, Altorki NK et al. Non small cell cancer. En: Devita VT, Hellman S, Rosenberg SA, eds. Lung cancer. Principles and practice. Lippincott, Williams and Wilkins; 2005. p. 189- 246.
2. Grupo de Trabajo de la SEPAR. Normativa actualizada (1998) sobre el diagnóstico y estatificación del carcinoma broncogénico. Arch Bronconeumol. 1998; 34: 437-52.
3. Hernández Hernández J. Neoplasias. Clínica, diagnóstico e indicaciones del tratamiento del carcinoma broncogénico. En: Martín Escribano P et al. Manual de Medicina Respiratoria. 2006; p. 1091-111.
4. McCaughan BC, Martini N, Bains MS, et al. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Torac Cardiovasc Surg. 1985; 89: 836-41.
5. Shahian DM, Neptune WB, Ellis FH. Pancoast tumors: improved survival with preoperative and postoperative radiotherapy. Ann Thorac Surg. 1987; 43: 32-80.
6. Sánchez de Cos Escuín J, Miravet L, Albal J, Núñez A, Hernández J, Castañar AM, et al. Estudio multicéntrico epidemiológico-clínico de cáncer de pulmón en España (Estudio Epiclip CP-2003). Arch Bronconeumol. 2006; 42: 446-52.
7. Sánchez de Cos Escuín J. Carcinoma broncogénico: epidemiología, factores etiológicos y manifestaciones clínicas. En: Álvarez-Sala JL, et al. Neumología clínica. Barcelona: Elsevier; 2010. p. 459-465.
8. Beckes MA,Spiro SG, Colice GL, et al. Initial evaluation of the patient with lung cancer. Symtoms, signs, laboratory tests and paraneoplastic syndroms. Chest. 2003; 123 (supple 1): 97-104.
9. Jameson JL, Johnson BR. Síndromes paraneoplásicos: hematológicos y endocrinológicos. En: Fauci AS, et al. Harrison, Principios de Medicina Interna. Mc Graw Hill; 2009. p. 617- 21.
10. Hansen M, Bork E. Peptide hormones in patients with lung cancer. Recent Results Cancer Res 1985; 99:180-186.
11. Mazzone PJ, Arroliga AC. Endocrine paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med 2003; 9:313-320.
12. Hiraki A, Ueoka H, Bessho A, et al. Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer 2002; 95:1706-1713.
13. Wozniak AJ, Gadgeel SM. Clinical presentation of small cell cancer. En: Pass HI, Carbone DP, eds. Lung cancer. Principles and Practice. Filadelfi a: Lippincott, Williams and Wilkins; 2005. p. 291-303.
14. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell cancer. J Clin Oncol 1986; 4;1191-1198.
15. Olan F, Portela M, Navarro C, et al. Circulating vascular endotelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. J Rheumatol 2004; 31:614-616.
16. Shneerson JM. Digital clubbing and hypertrophic osteoarthropathy. Br J Dis Chest 1981; 75:113-131.
17. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998; 114:1535-1537.
18. Stenseth JH, Clagett OT, Woolner LB. Hypertrophic pulmonary osteoarthropathy. Dis Chest 1967; 52:62-68.
19. Swash M, Schwartz MS. Paraneoplastic syndromes. In: Johnson RT, ed. Current therapy in neurologic disease. Philadelphia, PA: BC Decker;1990;236-243.
20. Dalmau J, Myrna R. Rosenfed. Síndromes neurológicos paraneoplásicos En: Fauci AS et al. Harrison, Principios de Medicina Interna. Mc Graw Hill; 2009. p. 623-8.
21. Drachman DB. Miastenia gravis y otras enfermedades de la unión neuromuscular. En: Fauci AS, et al. Harrison, Principios de Medicina Interna. Mc Graw Hill; 2009. p. 2672-7.